Trimetazidine in Practice: Review of the Clinical and Experimental Evidence

All of the following traditional agents for the management of stable angina pectoris include the symptomatic treatment with heart rate-lowering agents such as -blockers or non-dihydropyridine Ca-channel blockers, or ivabradinethe first selective sinus node I-f channel inhibitorvasodilatators and preventive use of angiotensin-converting enzyme inhibitors affect the parameters of circulation directly. Trimetazidine exerts its anti-ischemic action by modulating cardiac metabolism without altering the hemodynamic functions, therefore represents an excellent complementary potential to the conventional angina treatment. It has a beneficial effect on the inflammatory profile and endothelial function and shows diverse benefits by reducing the number and the intensity of angina attacks and improving the clinical signs and symptoms of myocardial ischemia given as monotherapy as well as combined with other antianginal agents. Patients undergoing coronary revascularization procedures or with comorbid left ventricular dysfunction and diabetes mellitus also benefit from the protective effects of trimetazidine.